“The Tide of Capital Ebbs and Flows with Technology”: BIO 2025 Investor Perspectives on AI and Digital Health

In the first half of 2025, two prominent Boston-based healthcare investment firms—Flare Capital Partners and Valspring Capital—offered rare insights at the BIO International Convention on how the venture capital landscape is evolving in artificial intelligence (AI) and digital health.

As Flare Capital’s partner and physician-investor Dr. Dan Gebremedhin outlined, AI has entered what he describes as its “third wave”: transitioning from big data-driven prediction models to robotic process automation, and now into the transformative era of generative AI. With enterprise clients showing a growing willingness to pay for AI-based solutions, early-stage funding (Seed and Series A) is experiencing a modest but notable resurgence—despite broader market contraction since the 2021 investment peak.

According to data shared at the session, while total capital deployed and deal volume have declined since their 2021 highs, median pre-money valuations and funding amounts for early-stage companies have remained stable or slightly increased. Series A and Series C rounds are particularly resilient. This suggests a market returning to fundamentals after an inflationary period, with investors gravitating towards quality, traction, and clear ROI.

Investment Criteria Recalibrated: From Valuation Hype to Operational Proof

The overheated valuations of 2021 and 2022—driven by cheap capital and macroeconomic enthusiasm—have given way to a more deliberate market environment. Investors now require proof of growth, profitability paths, and integration into real workflows. Dan emphasized, “If you want to be a unicorn, you need to show a credible path to $100 million in annual recurring revenue within five to six years.”

Mike O’Brien, partner at Valspring Capital, stressed that businesses must demonstrate not only product-market fit but also a well-articulated, replicable growth model. Their firm, currently deploying a $255 million debut fund, is actively evaluating AI-driven mental health and neurodiagnostic startups that leverage machine learning on tens of thousands of EEG brain scans to refine psychiatric treatment via TMS therapy and medication integration.

Investors are shifting their focus toward companies where AI delivers immediate operational results—cost reduction, time savings, or enhanced accuracy—not just future promises. SmarterDX, for instance, was acquired within three years of launch after its AI-based clinical documentation improvement platform was adopted by 30+ hospitals. Similarly, Suki’s evolution from voice-enabled EHR tools into a generative AI-enhanced ambient dictation platform underscores how real-world use cases accelerate both value creation and adoption.

Strategic Fundraising: Focus, Evidence, and Capital Discipline

The new rulebook for fundraising success in digital health and AI requires three pillars: niche focus, demonstrable ROI, and clear monetization strategy.

Investors now actively discourage broad, unfocused narratives (“we’ll be in all 50 states within 12 months”) and instead favor concentrated, high-impact operations in well-defined service lines or clinical populations. Startups that can show clear unit-level economics and revenue traction—before seeking capital to scale—are far more likely to attract attention.

They also caution founders to allow at least 6 months for the full fundraising cycle, from warm introductions to due diligence and legal execution. Both firms emphasized the critical importance of ongoing investor relationships: “Time is the best form of diligence,” said Dan. “We want to see if founders deliver what they said they would, over time.”

Warm referrals from trusted VC peers, advisors, or shared portfolio contacts remain the most common and effective entry points for deal flow.

Dual AI Playbooks: Prediction and Automation as Investment Anchors

While generative AI is a driving theme in today’s startup landscape, investors are increasingly focused on two major axes of AI value: black-box predictive models and workflow automation.

The former applies to drug development and trial simulations—where algorithms can identify optimal indications or trial designs. The latter is transforming repetitive tasks in healthcare, such as medical coding, documentation, and patient intake. SmarterDX and Suki exemplify successful applications of these approaches.

Valspring is also exploring a West Coast neuropsychiatry company combining AI-driven EEG analysis with customized TMS therapy, showcasing how AI is already embedded in diagnostic and therapeutic workflows.

More broadly, investors look for real deployment of AI today—not merely theoretical efficiencies in pitch decks. Solutions that integrate naturally into clinical operations and improve measurable outcomes stand out.

Globalization, Local Presence: Cross-Border Startups Face Hurdles and Hope

At the session, a founder from Hong Kong asked if early-stage AI ventures without legal incorporation could still attract U.S. investment. Both Flare and Valspring acknowledged their primary focus remains on North American entities—but noted exceptions are made for firms with U.S. presence, commercial traction, and localized teams.

Mike described one Swedish firm currently under review: while headquartered in Europe, it generates 50% of revenue in the U.S. and has an American president. “Being close to customers and familiar with their pain points is key,” he said. Dan added that their fund prefers startups with low scientific risk but high execution potential—particularly in enterprise healthcare software or clinical development support tools.

Final Advice to Founders: Narrow Your Focus, Sharpen Your Story

The closing message from both investors was resounding: the strongest companies in 2025 will be those that define their market precisely, deliver measurable impact, and execute with financial discipline.

Mike advised founders to “walk before you run,” emphasizing the value of unit-level profitability and G&A cost control. Growth is essential, but it must be rooted in operational health.

Dan added that Flare aims to back startups with the potential to become $100 million revenue businesses within five to six years. “The first question we ask is whether revenue is recurring or project-based. The second is customer size. The third is understanding whether your model truly supports enterprise adoption.”

Ultimately, venture funds need a few big wins. Startups that can demonstrate clarity, traction, and commercial scalability will stand out in a market still full of opportunity—albeit more discerning than ever.

Conclusion: Calm Amid the AI Storm, or the Beginning of a Healthtech Renaissance?

As capital flows recalibrate post-2021, the AI and digital health space finds itself at a crossroads. No longer is technological novelty alone sufficient to attract capital; today’s winning companies must also be grounded in use-case validation, commercialization discipline, and tangible patient or provider outcomes.

In 2025, the companies that thrive will be those that can do both: bring cutting-edge technology to market, and deliver it through workflows that solve real problems.

Author

Oscar Wu

Fostering knowledge sharing to create a more fluid and transparent information landscape.